Mipomersen sodium

米泊美生钠

Report date: 2022/05/19 14:20:28
NMEFirst In Class

Base Information

Drug NameMipomersen sodium
Drug Alias Name米泊美生KynamroISIS-301012
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionApolipoprotein B-100 inhibitors
TargetsApolipoprotein B-100
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipoproteinemia Type II +[6] 
Global Approved IndicationsHyperlipoproteinemia Type II
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2013/01/29
Country/TerritoryCzechiaCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLudwig Maximilians University Of MunichIonis Pharmaceuticals IncGenzyme Europe Bv +[4] 
Active IndicationsN/A
Inactive IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipoproteinemia Type II +[6] 

Other Information

ATC CodeC10AX11
Related LinksWikipediaDrugBankKEGG